IFOM
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

IFOM Trademark

Serial Number: 79256886 • Registration: 6297449

IFOM is a trademark filed by IFOM Fondazione Istituto FIRC di Oncologia Molecolare on September 20, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

IFOM Fondazione Istituto FIRC di Oncologia Molecolare (2 trademarks)

Via Adamello, 16

Entity Type: 99

Trademark Details

Filing Date

September 20, 2018

Registration Date

March 23, 2021

Published for Opposition

June 2, 2020

Goods & Services

Pharmaceutical preparations for use in dermatology; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for use in hematology; pharmaceutical preparations for the prevention of disorders of the skeletal system; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the treatment of disorders of the central nervous system related to cancer, aging and metabolic diseases; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of disorders of the circulatory system related to aging; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of hormonal disorders and diabetes; pharmaceutical cough preparations; preparations for treating colds; pharmaceutical preparations for the treatment of flu and headache; pharmaceutical preparations for the treatment of stomach disorders; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for treating muscular and/or rheumatological diseases; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for treating allergies; pharmaceutical agents affecting metabolism; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for use in oncology; diagnostic preparations and reagents for medical use in a clinic or medical laboratory; hormones; dietetic substances adapted for medical use, in particular, nutritional supplements, vitamin preparations, herbal supplements and preparations, nutritional drink mixes for use as meal replacements for medical use, meal replacement snacks for medical purposes; food and drinks for babies, infant formula and dietetic products for invalids, in particular food for babies, powdered milk for babies, foods for enteral feedings and dietetic foods adapted for medical purposes

Medical services, health care services in the field of oncology, aging and metabolic diseases, medical assistance, physical rehabilitation in the field of oncology; hospital services; consulting services in the field of medical care, namely, consultancy in the field of medical diagnosis, medical analysis and RNA or DNA analysis for cancer diagnosis and prognosis; consulting services relating to health care

Scientific and technological services, namely, scientific research, analysis, testing, diagnosis and screening in the field of oncology and cancer research; research and development in the field of oncology, aging and metabolic diseases; scientific and industrial research and analysis services, namely, scientific research, analysis, testing in the field of medicine; biological research and analysis; scientific, clinical and medical research in the field of radiology, chemotherapy, pharmacotherapy, coronary artery bypass surgery; basic and clinical research in the field of genetics, stem cell, immunodeficiency and neurodegenerative diseases, proteomics, bioinformatics, neurobiology and molecular biology and diabetes; scientific research in the field of medicine; consultancy in the field of scientific analysis; none of the foregoing to include educational testing

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Mar 23, 2026 REM3
NEW REPRESENTATIVE AT IB RECEIVED
May 28, 2023 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 14, 2021 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Jul 1, 2021 XXSS
GENERIC MADRID TRANSACTION CREATED
Jul 1, 2021 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 23, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 23, 2021 R.PR
TTAB RELEASE CASE TO TRADEMARKS
Feb 16, 2021 TMBN
OPPOSITION TERMINATED NO. 999999
Feb 16, 2021 OP.T
OPPOSITION DISMISSED NO. 999999
Feb 16, 2021 OP.D
REFUSAL PROCESSED BY IB
Dec 26, 2020 RFNP
OPPOSITION INSTITUTED NO. 999999
Dec 7, 2020 OP.I
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
Dec 1, 2020 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
Dec 1, 2020 OPNC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Oct 10, 2020 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 23, 2020 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Sep 23, 2020 OPNR
EXTENSION OF TIME TO OPPOSE RECEIVED
Jun 30, 2020 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 2, 2020 NPUB
PUBLISHED FOR OPPOSITION
Jun 2, 2020 PUBO
NOTIFICATION PROCESSED BY IB
May 29, 2020 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 13, 2020 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 13, 2020 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 13, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 24, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 17, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 17, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 17, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 17, 2020 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 17, 2020 ZZZX
WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST
Dec 18, 2019 PBSR
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 11, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 10, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 10, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 10, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 10, 2019 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 18, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 18, 2019 CRFA
ASSIGNED TO LIE
Nov 18, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 12, 2019 TROA
REFUSAL PROCESSED BY IB
Jun 22, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 31, 2019 RFCS
REFUSAL PROCESSED BY MPU
May 31, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 8, 2019 RFCR
NON-FINAL ACTION WRITTEN
May 7, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
May 4, 2019 MAFR
ASSIGNED TO EXAMINER
Apr 30, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 30, 2019 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Apr 29, 2019 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 18, 2019 REPR